Ucciferri et al. first showed that, in a small group of hypoxemic COVID-19 patients, canakinumab rapidly reduced CRP levels in the first 3 days, and increased the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) in the first 7 days of treatment compared to SOC alone.91 The gene discussed is CRP; the disease is COVID-19.